Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Contact Details: Technologiepark 4 Ghent Zwijnaarde 9052 Belgium Tel: 32 9 261.06.32 Fax: 32 9 261.06.28 Email: info@ablynx.com WWW: www.ablynx.com/

Recent Publications by Ablynx nv:
The development of nanobodies for therapeutic applications. Evolution has been continuously honing the design of antibodies to...	31st October, 2009	Ablynx NV, Technologiepark 4, B-9052 Zwijnaarde, Belgium.	Curr Opin Investig Drugs. 2009 Nov;10(11):1212-24.
Selecting and screening recombinant antibody libraries. During the past decade several display methods and other library screening...	22nd December, 2005	Ablynx NV, Technologiepark	Nat Biotechnol. 2005 Sep;23(9):1105-16. DOI Direct Link

BioNews Results for Ablynx nv:
Ablynx to receive milestone payment from Novartis	TradingMarkets:  Nov 19 2009 3:56PM Matching: ablynx nv
Ablynx NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released	PR inside:  Nov 16 2009 7:49AM Matching: ablynx nv

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 448 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: Ablynx NV Technologiepark 4 | ABLYNX APRIL 2009 | .

Search for more companies in Ghent

Search for more companies in Zwijnaarde

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Ablynx nv